Skip to main content

Table 3 List of adverse events from Grade 1/2 and Grade 3/4 evaluated according to the NCI-CTCAE (Version 3.0) toxicity classification

From: Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

System Organ Class

Adverse Event (CTCAE V3.0) - Number of pts. (%)

Grade

Grade 1/2

Grade 3/4

N

%

N

%

Blood/Bone Marrow

16

30.2

10

18.9

Gastrointestinal

39

73.6

6

11.3

Asthenia/Fatigue

33

62.3

10

18.9

Dermatology/Skin

23

43.4

2

3.8

Metabolic/Laboratory

19

35.8

4

7.5

 Hyperglycemia

 3

 5.7

 1

 1.9

 Hyperlipidemia

 11

 20.8

 2

 3.8

Infection

12

22.6

2

3.8

Neurology

7

13.2

  

Pulmonary/Upper Respiratory

6

11.3

  

Renal/Genitourinary

3

5.7

1

1.9

Cardiac General

1

1.9

2

3.8

Vascular

  

1

1.9